Key takeaways
Atogepant (Qulipta) and ubrogepant (Ubrelvy) are both medications that belong to the calcitonin gene-related peptide (CGRP) receptor blocker class and are used to manage migraines in adults. However, they differ in their specific uses and administration. Atogepant is used to prevent migraines and is taken once daily, while ubrogepant is used to treat sudden migraine attacks and can be taken up to twice a day, with doses at least 2 hours apart. Both medications are only available as brand-name products. Common side effects of atogepant include nausea, constipation, and sleepiness, while ubrogepant may cause nausea, sleepiness, and dry mouth. Both can interact with other medications, so it's important to discuss all medications you're taking with a healthcare professional.
